293780.KQ
AptaBio Therapeutics Inc.
KOE · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 5,310.00
−3.28%Year over year
Reported trailing growth
- Revenue
- +52.9%
- EBITDA
- -47.8%
- EBIT
- +4.6%
- EPS
- +47.2%
- Free cash flow
- -16.5%
- Operating cash flow
- -18.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +324.5%
- EBITDA
- +37.1%
- EBIT
- +17.8%
- Net income
- +44.4%
- EPS
- +52.3%
- Free cash flow
- -23.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026